[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100495957":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":22,"centralContacts":29,"locations":35,"responsibleParty":54,"collaborators":58,"id":84,"slug":85,"hasResults":86,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":10,"eligibilityCriteria":90,"healthyVolunteers":86,"sex":91,"minAge":92,"maxAge":10,"enrollmentInfo":93,"targetDuration":10,"studyType":96,"phases":10,"briefSummary":97,"conditions":98,"keywords":102,"overallStatus":37,"whyStopped":10,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":113},{"fullName":5,"class":6},"Changhai Hospital","OTHER",[8,13],{"label":9,"type":10,"description":10,"interventionNames":11},"Mucinous tumour group",null,[12],"Diagnostic Test: cfDNA methylation sequencing and proteome analysis",{"label":14,"type":10,"description":10,"interventionNames":15},"Non-mucinous tumour group",[12],[17],{"type":18,"name":19,"description":20,"armGroupLabels":21,"otherNames":10},"DIAGNOSTIC_TEST","cfDNA methylation sequencing and proteome analysis","Sequencing of cfDNA methylation and proteomic analysis of two sets of capsular fluid samples",[9,14],[23,26],{"name":24,"affiliation":5,"role":25},"Shiyu Li","PRINCIPAL_INVESTIGATOR",{"name":27,"affiliation":5,"role":28},"Chengye Pan","STUDY_CHAIR",[30],{"name":31,"role":32,"phone":33,"phoneExt":10,"email":34},"Kaixuan Wang","CONTACT","021-31166666","lizfish@126.com",[36],{"facility":5,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"RECRUITING","Shanghai","Shanghai Municipality","200433","China","CN",{"type":44,"coordinates":45},"Point",[46,47],121.45806,31.22222,{"lat":47,"lon":46},[50],{"name":51,"role":32,"phone":52,"phoneExt":10,"email":53},"Kaixuan Wang, MD","86-21-31161353","wangkaixuan224007@sina.com",{"type":55,"investigatorFullName":56,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Zhaoshen Li","Director of Gastroenterology Department of Changhai Hospital",[59,62,64,66,68,70,72,74,76,78,80,82],{"name":60,"class":61},"Oriental Hepatobiliary Surgery Hospital Affiliated to Naval Military Medical University","UNKNOWN",{"name":63,"class":6},"Zhejiang University",{"name":65,"class":6},"The First Affiliated Hospital of Nanchang University",{"name":67,"class":6},"West China Hospital",{"name":69,"class":6},"LanZhou University",{"name":71,"class":6},"First Affiliated Hospital Xi'an Jiaotong University",{"name":73,"class":6},"Peking University Cancer Hospital & Institute",{"name":75,"class":6},"First Hospital of China Medical University",{"name":77,"class":6},"First Affiliated Hospital of Guangxi Medical University",{"name":79,"class":6},"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School",{"name":81,"class":6},"The Second Affiliated Hospital of Baotou Medical College",{"name":83,"class":6},"Shandong Province Third hospital","100495957","construction-of-molecular-diagnostic-marker-model-for-pancreatic-cystic-tumors-based-on-pancreatic-cystic-fluid-samples-100495957",false,"NCT05737953","Construction of Molecular Diagnostic Marker Model for Pancreatic Cystic Tumors Based on Pancreatic Cystic Fluid Samples","Construction of Molecular Diagnostic Marker Models for Pancreatic Cystic Tumors Based on CfDNA Methylation Sequencing and Proteomic Analysis of Pancreatic Cystic Fluid Samples","Inclusion Criteria:\n\n* Subjects are ≥ 18 years old, regardless of gender;\n* Preoperative imaging examination (EUS, CT, MRI) diagnosed cystic mass of pancreas and suspected cystic tumor;\n* Subjects voluntarily accepted radical resection of pancreatic cystic tumors;\n* Subjects or family members voluntarily sign the informed consent form for clinical research.\n\nExclusion Criteria:\n\n* The excised sample does not contain cystic components, or the cystic fluid cannot be collected;\n* Receive tumor-related treatment (radiotherapy, chemotherapy, immunotherapy, etc.) before operation;\n* Receive antibiotic treatment within 1 week before operation;\n* Subjects refused to accept radical resection of pancreatic cystic tumor, or had any situation that they could not accept radical resection of pancreatic cystic tumor;\n* The subjects or their families refused to sign the informed consent form for clinical research.","ALL","18 Years",{"count":94,"type":95},100,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to test in patients with cystic tumor of pancreas. The main questions it aims to answer are:\n\nScreening of molecular diagnostic markers for pancreatic cystic tumors by cfDNA methylation sequencing of pancreatic cystic fluid and proteomic assays to distinguish benign from malignant and mucinous\u002Fnon-mucinous, correlate with pathological features, and find molecular features associated with the degree of malignancy.\n\nParticipants will Provide post-operative cyst fluid specimens.",[99,100,101],"Pancreatic Neoplasms","DNA Methylation","Proteome",[103],"Pancreas cystic neoplasm","2025-02-07",{"date":106,"type":107},"2025-02-11","ACTUAL",{"date":109,"type":107},"2023-03-01",{"date":111,"type":95},"2025-07-31",{"name":56,"class":6},1]